Altimmune (ALT) announced the appointment of Linda Richardson to the role of Chief Commercial Officer, effective September 16, 2025. Richardson joins the Company with more than 30 years of experience in sales and marketing, commercial, corporate and business development across a range of therapeutic areas, including metabolic disease, hepatology, cardiovascular and addiction medicine.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALT:
- Altimmune’s Earnings Call Highlights NASH Trial Success and Financial Strength
- Altimmune rallies after FDA accepts liver stiffness as MASH endpoint
- Altimmune announces FDA Fast Track designation for pemvidutide
- Altimmune price target lowered to $24 from $26 at UBS
- Altimmune’s Pemvidutide Advances Towards Phase 3 Trials with Promising Data and Strategic Leadership